Stocks and Investing Stocks and Investing
Mon, April 25, 2022

Matthew Harrison Downgraded (ALNY) to Hold and Decreased Target to $178 on, Apr 25th, 2022


Published on 2024-10-27 20:36:47 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Downgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Hold and Decreased Target from $210 to $178 on, Apr 25th, 2022.

Matthew has made no other calls on ALNY in the last 4 months.



There are 5 other peers that have a rating on ALNY. Out of the 5 peers that are also analyzing ALNY, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $103 on, Friday, February 11th, 2022


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $400 on, Tuesday, April 12th, 2022
  • David Lebowitz of "Citigroup" Initiated at Strong Buy and Held Target at $223 on, Tuesday, March 1st, 2022
  • Etzer Darout of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $170 on, Thursday, February 3rd, 2022
  • Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
Contributing Sources